Cancer Anorexia-Cachexia Syndrome – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome – Pipeline Review, H1 2017’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome

– The report reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cancer Anorexia-Cachexia Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Cancer Anorexia-Cachexia Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acacia Pharma Ltd

Aeterna Zentaris Inc

Aphios Corp

Incyte Corp

Lakewood-Amedex Inc

Novartis AG

Obexia AG

PsiOxus Therapeutics Ltd

RaQualia Pharma Inc

Viking Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cancer Anorexia-Cachexia Syndrome Overview

Cancer Anorexia-Cachexia Syndrome Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cancer Anorexia-Cachexia Syndrome Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cancer Anorexia-Cachexia Syndrome Companies Involved in Therapeutics Development

Acacia Pharma Ltd

Aeterna Zentaris Inc

Aphios Corp

Incyte Corp

Lakewood-Amedex Inc

Novartis AG

Obexia AG

PsiOxus Therapeutics Ltd

RaQualia Pharma Inc

Viking Therapeutics Inc

Cancer Anorexia-Cachexia Syndrome Drug Profiles

(formoterol fumarate + megestrol acetate) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anamorelin hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-380 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-1889 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLN-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-400 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Foxo1-nRNA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-1940 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OBX-1201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize Melanocortin Receptor for Cancer Cachexia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Cancer Cachexia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer Anorexia-Cachexia Syndrome Dormant Projects

Cancer Anorexia-Cachexia Syndrome Discontinued Products

Cancer Anorexia-Cachexia Syndrome Product Development Milestones

Featured News & Press Releases

Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen

Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer

Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology

Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL

Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference

Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102

Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130

Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130

Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference

Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study

Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia

Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Acacia Pharma Ltd, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Aeterna Zentaris Inc, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Aphios Corp, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Incyte Corp, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Lakewood-Amedex Inc, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Novartis AG, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Obexia AG, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by PsiOxus Therapeutics Ltd, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by RaQualia Pharma Inc, H1 2017

Cancer Anorexia-Cachexia Syndrome Pipeline by Viking Therapeutics Inc, H1 2017

Cancer Anorexia-Cachexia Syndrome Dormant Projects, H1 2017

Cancer Anorexia-Cachexia Syndrome Dormant Projects, H1 2017 (Contd..1), H1 2017

Cancer Anorexia-Cachexia Syndrome Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports